Pınar ZARAKOLU[1]
Gökhan METAN[2]
Belgin ALTUN[1]
Gülşen HASÇELİK[3]
Serhat ÜNAL[1]

[1] Department of Medicine,
Section of Infectious Diseases,
Faculty of Medicine,
Hacettepe University,
Ankara - TURKEY

[2] Department of Infectious Diseases
and Clinical Microbiology,
Faculty of Medicine,
Erciyes University,
Kayseri - TURKEY

[3] Central Laboratories,
Adult Hospital,
Hacettepe University,
Ankara - TURKEY

Antimicrobial susceptibility, inducible macrolide-lincosamide-streptogramin B, and clonal diversity patterns of nosocomial methicillin-resistant *Staphylococcus aureus* strains isolated in Hacettepe University adult hospital

Aim: Nosocomial infections due to methicillin resistant *Staphylococcus aureus* (MRSA) are an important problem with limited therapeutic options. The aim of this study was to determine the vancomycin, teicoplanin, linezolid, tigecycline, erythromycin, gentamicin, ciprofloxacin, rifampin, trimethoprim/sulfamethoxazole, and clindamycin susceptibility, inducible macrolide-lincosamide-streptogramin B ($iMLS_B$) resistance, and clonal diversity patterns of 109 *mecA* positive *Staphylococcus aureus* strains isolated from patients with nosocomial infections in Hacettepe University Adult Hospital between 2002 and 2004.

Materials and methods: The nosocomial isolates of S. aureus from various clinical samples (58 blood, 45 pus, 6 catheter) were identified by Sceptor (Becton Dickinson, USA) automated system. Polymerase chain reaction (PCR) was performed for the presence of *mecA* gene of the MRSA isolates. The susceptibility to vancomycin, teicoplanin, linezolid, and tigecycline was determined by Etest (AB Biodisk, Sweden) and to the other antibiotics by disk diffusion methods according to the CLSI recommendations. Inducible macrolide-lincosamide-streptogramin B ($iMLS_B$) resistance phenotypes were determined by the double disk method. Pulse field gel electrophoresis (PFGE) was performed to examine the clonal diversity.

Results: All MRSA strains were susceptible to vancomycin, teicoplanin, linezolid, and tigecycline with MIC_{90} (μg/mL) values of 2, 2, 2, and 0.25, respectively. The isolates were highly resistant (≥90%) to gentamicin, ciprofloxacin, and rifampin, whereas the susceptibility to trimethoprim/sulfamethoxazole was 89%, to clindamycin was 62%, and to erythromycin was 46%. $IMLS_B$ resistance was determined among 13% of the MRSA strains. Thirteen different clones were shown by PFGE, whereas 80% of the isolates were in a dominant clone.

Conclusion: Vancomycin, teicoplanin, linezolid, and tigecycline were highly active against nosocomial isolates of MRSA in our hospital. Although these are effective therapeutic options for MRSA, the high rate of cross-contamination of the patients is a matter of concern. We should pay more attention to infection control practices.

Key words: Methicillin-resistant Staphylococcus aureus (MRSA), antibiotic susceptibility, inducible macrolide-lincosamide-streptogramin B (iMLSB), pulse field gel electrophoresis (PFGE)

Correspondence

Pınar ZARAKOLU
Department of Medicine,
Section of Infectious Diseases,
Faculty of Medicine,
Hacettepe University,
06100, Ankara - TURKEY

zarakolu@hacettepe.edu.tr

Hacettepe Üniversitesi erişkin hastanesi'nde izole edilen hastane enfeksiyonu etkeni metisiline dirençli *Staphylococcus aureus* suşlarının antimikrobiyallere duyarlılık, indüklenebilir makrolid-linkozamid-streptogramin B direnç ve klonal benzerlik durumları

Amaç: Metisiline dirençli *Staphylococcus aureus* (MRSA)'a bağlı gelişen nozokomiyal enfeksiyonlar tedavide az sayıda seçenek olması nedeniyle önemli bir sorun oluşturmaktadır. Bu çalışmada Hacettepe Üniversitesi Erişkin Hastanesi'nde 2002-2004 yılları arasında hastane enfeksiyonu etkeni olarak izole edilen *mecA* geni pozitif 109 *Staphylococcus aureus* suşunun vankomisin, teikoplanin, linezolid, tigesiklin, eritromisin, gentamisin, siprofloksasin, rifampin, trimethoprim-sulfametoksazol

ve klindamisine karşı duyarlılık, indüklenebilir makrolid-linkozamid-streptogramin B (iMLS$_B$) direnç ve klonal benzerlik durumlarının belirlenmesi amaçlanmıştır.

Yöntem ve gereçler: Farklı klinik örneklerden (58 kan, 45 püy, 6 kateter) izole edilen *S. aureus* suşlarının tür düzeyindeki tanımlaması Sceptor (Becton Dickinson, ABD) otomatize sistemi ile yapılmıştır. Otomatize sistemden metisiline dirençli *S. aureus* (MRSA) olarak rapor edilen izolatların *mecA* geni varlığı PZR yöntemiyle gösterilmiştir. Vankomisin, teikoplanin, linezolid ve tigesiklin için duyarlılık testleri Etest (AB Biodisk, İsveç) ile üretici firma önerilerine uygun olarak gerçekleştirilmiştir. Diğer antibiyotiklere karşı duyarlılık disk difüzyon yöntemi ile belirlenip, sonuçlar CLSI kriterlerine göre yorumlanmıştır. İMLS$_B$ direnci çift disk difüzyon, suşlar arasındaki klonal benzerlik 'pulse field gel electrophoresis (PFGE)' yöntemi ile belirlenmiştir.

Bulgular: MRSA izolatlarının vankomisin, teikoplanin, linezolid ve tigesiklin MİK$_{90}$ değerleri sırasıyla 2, 2, 2 ve 0,25 µg/ml ve tümü bu antibiyotiklere duyarlı olarak saptanmıştır. Bununla birlikte tüm izolatlar gentamisin, siprofloksasin ve rifampisine yüksek oranda (≥% 90) dirençli; trimetoprim/sülfametaksazole % 89, klindamisine % 62 ve eritromisine % 46 oranında duyarlı bulunmuştur. MRSA izolatlarının % 13'ünde iMLS$_B$ direnci saptanmıştır. PFGE analizi sonucunda 13 farklı klon saptanmış, izolatların % 80'inin belli bir tek klonda yer aldığı gözlenmiştir.

Sonuç: Vankomisin, teikoplanin, linezolid ve tigesiklin hastanemizde izole edilen MRSA suşlarına karşı yüksek düzeyde aktivite göstermektedir. MRSA enfeksiyonlarının tedavisi için etkin seçeneklerimiz olmasına rağmen, klonal analiz sonuçlarına göre hastalar arasında yüksek oranda çapraz bulaş saptanması endişe uyandırmaktadır. Bu durum enfeksiyon kontrol önlemlerine daha fazla dikkat göstermemiz gerektiğini göstermektedir.

Anahtar sözcükler: Metisiline Dirençli *Staphylococcus aureus* (MRSA), antibiyotiklere duyarlılık, makrolid-linkozamid-streptogramin direnci (iMLS$_B$), pulse field gel electrophoresis (PFGE)

Introduction

Methicillin-resistant *Staphylococcus aureus* (MRSA) is one of the most important causes of nosocomial infections worldwide. It is known to be encoded by the *mecA* gene and is mostly multi-resistant to a wide range of antibiotics (1).

The glycopeptides vancomycin, teicoplanin and an oxazolidinone linezolid have been regarded as the drug of choice for the treatment of MRSA infections (2). However, vancomycin-intermediate (VISA) and -resistant isolates of *S. aureus* (VRSA) have been described in some countries (3). Recently, tigecycline represents an exciting new class of glycylcycline antimicrobial agents for the treatment of multi-drug resistant gram-positive bacteria (4).

This study was conducted to determine the vancomycin, teicoplanin, linezolid, tigecycline, as well as erythromycin, gentamicin, ciprofloxacin, rifampin, trimethoprim/sulfamethoxazole, and clindamycin susceptibility, inducible macrolide-lincosamide-streptogramin B (iMLS$_B$) resistance, and clonal diversity patterns of *mecA* positive *S. aureus* strains isolated from patients with nosocomial infections in Hacettepe University Adult Hospital between 2002 and 2004.

Methods

Strains

All MRSA isolates from clinical samples of inpatients with nosocomial infections at Hacettepe University Adult Hospital between 2002 and 2004 were included in the study. Only one isolate from each patient was included in the study. The identification of the isolates was made by Sceptor automated system (Becton Dickinson, USA) and methicillin resistance was confirmed by the presence of the *mecA* gene by polymerase chain reaction (PCR), which is considered the 'gold standard' in the determination of heterogeneous resistance. Pulse field gel electrophoresis (PFGE), which is the 'gold standard' as a genotypic typing method, was performed to examine the clonal diversity. The isolates were stored at -80 °C until studied. *S. aureus* ATCC 29213, *S. aureus* 27R, and *S. aureus* 8328 were included as control strains.

Antibiotic susceptibility tests

Susceptibility testing against erythromycin (15 µg), gentamicin (10 µg), ciprofloxacin (5 µg), rifampin (5 µg), trimethoprim/sulfamethoxazole (TMP-SMX, 1.25/23.75 µg), and clindamycin (2 µg) disks (Oxoid, UK) was performed on Mueller Hinton agar (MHA) (Oxoid, UK) incubated at 35 °C for 12-16 h. In addition, Etest strips (AB Biodisk, Sweden) were used to test the susceptibility against vancomycin, teicoplanin, linezolid, and tigecycline with an inoculum of McFarland 2.0 onto brain heart infusion agar (BHIA) (Oxoid, UK) according to the manufacturer's recommendations. The results were interpreted according to CLSI criteria (5). Moreover, inducible and constitutive macrolide-lincosamide-streptogramin B (iMLS$_B$) resistance phenotypes were determined by double disk method with erythromycin and clindamycin disks placed at a distance of 15-20 mm. After 18 h of incubation at 37 °C, blunting of the clindamycin zone of inhibition near the erythromycin disk indicated iMLS$_B$ resistance and resistance to both erythromycin and clindamycin indicated constitutive MLS$_B$ resistance (6). For tigecycline, interpretive criteria from the US Food and Drug Administration packaging insert were applied as susceptible ≤0.5 µg/mL (7).

PCR

The isolation of bacterial DNA was performed as described previously (8). Amplification was performed in a mixture consisting of 50 mM Tris (pH 8.3), 50 mM KCl, 2.5 mM MgCl$_2$, 0.2 mM of deoxyribonucleotide triphosphates (dATP, dGTP, dCTP, and dTTP), 50 pmol of each primer, 0.5 U Taq DNA Polymerase (MBI Fermentas, USA), and 5 mL of staphylococcal DNA extract. The sequences of the primers mecA1 and mecA2 were 5' GTT GTA GTTB GTC GGG TTT GG 3' and 5' CCA CCC AAT TTG TCT GCC AGT TTC 3', respectively. The amplification was performed in a Flexigene (Techne, Cambridge, UK) thermalcycler by a program consisting of an initial denaturation step at 94 °C for 4 min; this was followed by 30 cycles of 94 °C for 30 s, 55 °C 30 s, 72 °C 2 min, and 72 °C for 5 min (9). PCR products were then separated by electrophoresis in 1.5% agarose gels with 1× Tris-acetate EDTA (TAE) running buffer (40 mM Tris-acetate, 1 mM EDTA) and visualized on a UV transilluminator and photographed. The molecular weight standard was φx174 (MBI Fermentas, USA). Isolates with the mecA genotype showed a 1817 bp band.

PFGE

MRSA DNA embedded in agarose blocks was prepared as described by Lencastre (10). The DNA fixed in the agarose disk was incubated for 20 h in 45 µL of restriction buffer and Sma I (20 U). The reaction was stopped with 5 µL of loading buffer. Gels with 1.1% agarose (Genexis Spech bach, Germany) were prepared in 0.5 × TBE buffer (50 mM boric acid, 0.2 mM EDTA). PFGE was carried out by General Navigator, Pharmacia (Uppsala, Sweden). The running conditions were performed for 22 h at 14 °C at 150 V. Pulse times were 20 s for 15 h, 35 s for 7 h, 50 s for 15 h, and 90 s for the last 3 h.

Results

A total of 109 MRSA isolates from different clinical samples (58 blood, 45 pus, 6 catheter) were included in the study. The methicillin resistance of all *S. aureus* isolates included in the study was confirmed by detection of the mecA gene. All isolates were multi-drug resistant (≥3 groups of antibiotics). They were highly resistant (≥90%) to the antimicrobials gentamicin, ciprofloxacin, and rifampin, whereas the susceptibility to TMP-SMX was 89%, to clindamycin was 62%, and to erythromycin was 46%. Of the 68 clindamycin-susceptible strains, 14 had iMLS$_B$ resistance. Overall 13% of the isolates had iMLS$_B$ resistance. All MRSA strains were susceptible to vancomycin, teicoplanin, linezolid, and tigecycline with MIC$_{90}$ (µg/mL) values of 2, 2, 2, and 0.25 respectively (Table).

PFGE analysis of genomic DNA from 109 isolates revealed 13 different clones (Figure). One epidemic clone (clone A) was identified for 87 isolates (79.8%). Six other clones contained 5, 3, 2, 2, 2, and 2 isolates, respectively. There were also 6 different sporadic clones each contained a single isolate.

Discussion

MRSA is one of the leading causes of nosocomial infections worldwide. In a multicenter study, the prevalence of MRSA infections was reported to be

Table.   Antimicrobial resistance of 109 nosocomial MRSA
          strains isolated in Hacettepe University Adult Hospital
          between 2002 and 2004.

Antimicrobial agent	Resistance (%)
Clindamycin	38*
Erythromycin	54
TMP-SXT	11
Rifampin	90
Gentamicin	93
Ciprofloxacin	95
Vancomycin	-
Teicoplanin	-
Linezolid	-
Tigecycline	-

* Although 62% of the strains were susceptible to clindamycin,
13% had iMLS$_B$ resistance

>40% in southern and western European hospitals
(11). The prevalence of methicillin resistance among
nosocomial *S. aureus* isolates was 70% in Hacettepe
University Adult Hospital between 2000 and 2004 (12,
Unpublished data). According to PFGE analysis, a
dominant clone was prevalent in our hospital, which
is a serious concern for an effective infection control
program. Contact isolation is performed for patients
infected with MRSA in our hospital. All intensive care
units are visited daily by an infection control nurse.
There are reminder posters about the infection
control measures on the walls and cautionary cards
are placed at the bedsides of the patients who are

infected with MRSA. Alcohol-based hand rinses are
available at the bedsides of patients infected with
MRSA in wards and regardless of infection with
MRSA at the ICU. Since MRSA colonization often
precedes infection there is great interest in
decolonizing persons who harbor these bacteria. The
most extensive research in MRSA decolonization has
been conducted with mupirocin, which is applied to
the anterior nares 2-3 times/day for 5 days. Routine
decolonization is not prudent unless MRSA
colonization is confirmed in the nares or other site.
Screening for MRSA colonization is not a routine
infection control practice in our hospital and we do
not use mupirocin for decolonization. The
compliance to infection control practices such as hand
hygiene and isolation precautions is poor in our
hospital, mainly due to the overcrowding of patients
and the inadequate number of medical staff.

The high rates of resistance to ciprofloxacin,
rifampin, and gentamicin were significant. Similar
results had been reported from a different center in
Turkey, recently (13). The susceptibility rate of MRSA
strains to TMP-SMX is 89% in this study. Moreover,
Samra et al. reported the TMP-SMX susceptibility of
nosocomial MRSA strains as 86% (14).

Although 62% of the strains were susceptible to
clindamycin, the high rate of erythromycin resistance
raised the question of inducible resistance and iMLS$_B$
resistance was determined in 13% of MRSA isolates.
Different resistance rates have been reported from


Figure.   PFGE analysis of different clonal patterns of MRSA isolates.
          Lanes 1, 6, 13, 17, 18 pattern A, lane 2 pattern L, lane 3 pattern E, lane 4 pattern
          N, lane 5 pattern F, lane 7 pattern K, lane 8 pattern C, lane 9 pattern G, lane 10
          pattern D, lane 11 pattern H, lane 12 pattern M, lane 16 pattern B, lanes 15, 16
          pattern O, lane 19 NCTC isolate.

different geographical regions for iMLS$_B$ resistance. Delialioglu et al. reported 5.4% inducible phenotype among 128 MRSA strains from Turkey (15). Inducible clindamycin resistance has been reported in 5.6% of 108 MRSA isolates from Başkent University Hospital, Turkey (16). However, in a study from Maryland, USA, that examined 161 clinical MRSA isolates for iMLS$_B$ resistance, 56% of the strains harbored iMLS$_B$ resistance (17), and similar high rates were also reported from India (18). These results clearly indicate that, based on institution and geographic region, the prevalence rates of iMLS$_B$ phenotypes vary. The reason for this is not clear and it is a good subject for further research. Vancomycin, teicoplanin, linezolid, and tigecycline had very good activity against MRSA isolates in this study. Glycopeptides are recommended therapeutic options for MRSA infections, but acquired resistance to vancomycin in staphylococci has become known in recent years and many clinicians are concerned about the significance of acquired resistance that could show a rapid progress in clinical use (19-24). Furthermore, teicoplanin resistant *S. aureus* has been reported from the Mediterranean region (25,26). There has been no VRSA report in Turkey, but there was a report of VISA strains isolated from various clinical samples in 2005 (27). Amongst 256 MRSA isolates 46 had reduced susceptibility to vancomycin. Twelve of the 46 patients with hetero-VISA had a history of previously treatment with vancomycin or teicoplanin. In another study, 1 (1.2%) out of 81 *S. aureus* isolates had intermediate resistance to teicoplanin (MIC 16 mg/L), but VISA was not detected. Six strains of *Staphylococcus haemolyticus* (13%) out of 54 coagulase negative staphylococci (CoNS) were detected to have heterogeneously reducing susceptibility to vancomycin (MICs ranged between 5 and 8 mg/L) (28). In this study we did not examine the heterogeneous resistance to glycopeptides. Besides resistance, the vancomycin MIC may have important consequences on the efficacy of this antibiotic and on mortality in patients with bacteremia due to MRSA. Mortality associated with MRSA bacteremia was significantly higher when vancomycin was empirically used for treatment of infection with strains with a high vancomycin MIC (>1 mg/mL) (29).

Gram-positive cocci are rarely resistant to linezolid. A recent study examined the linezolid susceptibility of 1930 isolates of MRSA collected from the different regions of the United States; 99.9% were susceptible to linezolid (30). Two clinical isolates of MRSA resistant to linezolid have been reported from different parts of the world (31,32). There are 2 other reports about linezolid susceptibility of MRSA strains in Turkey. The first study includes 127 MRSA strains and the second includes 38, and all are susceptible to linezolid (33,34). Clinical outcomes are significantly better with linezolid than with vancomycin in several indications (35,36). The efficacy and safety of linezolid and vancomycin were compared for the treatment of nosocomial pneumonia, complicated skin and soft-tissue infections, or sepsis caused by MRSA infections in Japan, recently. One hundred patients received linezolid and 51 received vancomycin with outcomes evaluated at the end of therapy (EOT). At EOT, clinical success rates in the MRSA microbiologically evaluable population were 62.9% and 50.0% for the linezolid and vancomycin groups, respectively; and microbiological eradication rates were 79.0% and 30.0% in the 2 groups, respectively (P ≤ 0.0001). Reversible anemia (13%) and thrombocytopenia (19%) were reported more frequently in linezolid patients (37).

Tigecycline, a new glycylcycline antibiotic, has shown promising in vitro activity against many common pathogens, including MRSA. The MIC90 of tigecycline against *S. aureus* was 0.25 µg/mL in a study performed at 40 study centers in 11 countries (38). Tigecycline was shown to be non-inferior to combination vancomycin-aztreonam regimens and exhibited high clinical success rates for complicated soft tissue infections. MIC90 values for tigecycline were uniformly low for both susceptible and resistant pathogens. Adverse events were similar in incidence for both patient populations, with nausea and vomiting reported more frequently with tigecycline treated patients while rash and elevated liver transaminases were most commonly observed in the vancomycin-aztreonam treatment group (39). A randomized (3:1), double-blind, multicentre, phase 3 study compared the safety and efficacy of tigecycline with vancomycin in hospitalized patients with MRSA.

Clinical cure rates in the microbiologically evaluable population (n = 117) were 81.4% (70 of 86 patients) with tigecycline and 83.9% (26 of 31 patients) with vancomycin (40).

In conclusion, glycopeptides and linezolid are effective drugs for MRSA infections in our hospital.

Moreover, tigecycline is a promising alternative for the treatment of MRSA infections. Even though there are effective therapeutic options, surveillance of resistance should guide the selection of empirical therapy and continuous attention should be paid to infection control measures.

References

1. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN et al and the SENTRY Participants Group. Survey of infections due to *Staphylococcus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(suppl 2): 114-132.

2. Lode H. Management of serious nosocomial bacterial infections: do current therapeutic options meet the need? Clin Microbiol Infect 2005; 11: 778-87.

3. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant *Staphylococcus aureus*. Clin Microbiol Infect 2006; Suppl 1: 16-23.

4. Squires RA, Postier RG. Tigecycline for the treatment of infections due to resistant Gram-positive organisms. Expert Opin Investig Drugs 2006; 15: 155-62.

5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. M100-A15. Wayne, PA, CLSI, 2005.

6. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in *Staphylococcus aureus* and coagulase-negative staphylococci. J Clin Microbiol 2003; 41: 4740-4.

7. Wyeth Pharmaceuticals Inc. Tygacil Product Insert. Philadelphia, PA, USA, 2007. http://www.tygacil.com (last accessed 24 April 2007).

8. McLaughlin RE, Ferreti JJ. Molecular approaches to the identification of Streptococci. In: Woodford N, Jhonson AP, eds. Molecular Bacteriology: Protocols and Clinical Applications, Totowa, New Jersey: Humana Press Inc. 1998: 117-138.

9. Unal S, Werner K, DeGirolami P, Barsanti F, Eliopoulos G. Comparison of tests for detection of methicillin-resistant *Staphylococcus aureus* in a clinical microbiology laboratory. Antimicrobial Agents Chemother 1994; 38: 345-347.

10. Lencastre H, Cauto I, Santos I, Melo-Cristino J, Torres-Pereira A, Tomasz A: Methicillin-Resistant *Staphylococcus aureus* disease in a Portuguese Hospital: Characterization of clonal types by a combination of DNA typing methods. Eur J Clin Microbiol Infect Dis 1994; 13: 64-73.

11. Tiemersma EW, Bronzwaer SL, Lyytikäinen O, Degener JE, Schrijnemakers P, Bruinsma N et al and European Antimicrobial Resistance Surveillance System Participants. Methicillin-resistant *Staphylococcus aureus* in Europe, 1999-2002. Emerg Inf Dis 2004; 10(9): 1627-34.

12. Nosocomial Infections Surveillance Report of Hacettepe University Adult Hospital, 2000-2004.

13. Tosun I, Udo EE, Noronha B, Caylan R, Aydin F, Yetiskul S et al. Emergence of rifampicin resistance in methicillin-resistant *Staphylococcus aureus* isolated at a Turkish university hospital. Microb Drug Resist 2005; 11: 48-52.

14. Samra Z, Ofer O, Shmuely H. Susceptibility of methicillin-resistant *Staphylococcus aureus* to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics. Isr Med Assoc J 2005; 7: 148-50.

15. Delialioglu N, Aslan G, Ozturk C, Baki V, Sen S, Emekdas G. Inducible clindamycin resistance in staphylococci isolated from clinical samples. Jpn J Infect Dis 2005; 58: 104-6.

16. Azap OK, Arslan H, Timurkaynak F, Yapar G, Oruc E, Gagir U. Incidence of inducible clindamycin resistance in staphylococci: first results from Turkey. Clin Microbiol Infect 2005; 11: 582-584.

17. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37: 1257-60.

18. Navaneeth BV. A preliminary in vitro study on inducible and constitutive clindamycin resistance in *Staphylococcus aureus* from a South Indian tertiary care hospital. Int J Infect Dis 2006; 10: 184-185.

19. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM et al. Vancomycin-intermediate Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological characterization of infections caused by *Staphylococcus aureus* with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36: 429-439.

20. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant *Staphylococcus aureus* clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.

21.   Liu C, Chambers HF. *Staphylococcus aureus* with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47: 3040-3045.

22.   Centers for Disease Control and Prevention. Vancomycin-resistant *Staphylococcus aureus*-Pennsylvania. MMWR Morbid Mort Week Rep. 2002; 51: 902.

23.   Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP et al and the Vancomycin-Resistant *Staphylococcus aureus* Investigative Team. Infection with vancomycin-resistant *Staphylococcus aureus* containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-1347.

24.   Ploy MC, Grelaud C, Martin C, De Lumley L, Denis F. First clinical isolate of vancomycin-intermediate *Staphylococcus aureus* in a French hospital. Lancet 1998; 351: 1212.

25.   Reverdy ME, Jarraud S, Bobin-Dubreux S, Boulton ML, Tenover FC, Downes FP et al. Incidence of *Staphylococcus aureus* with reduced susceptibility to glycopeptides in two French hospitals. Clin Microbiol Infect 2001; 7: 267-272.

26.   Borg MA, Zerafa R, Morrison D, Cuschieri P. Incidence of glycopeptide hetero-intermediate *Staphylococcus aureus* strains in Maltese hospitals. Clin Microbiol Infect 2005; 11: 405-7.

27.   Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hascelik G. Methicillin-resistant *Staphylococcus aureus* heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 2005; 56: 519-23.

28.   Nakipoglu Y, Derbentli S, Cagatay AA, Katranci H. Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital. BMC Infect Dis 2005; 5: 31.

29.   Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. Clin Infect Dis 2008; 46: 193-200.

30.   Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 2008; 62: 416-26.

31.   Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L et al. Linezolid resistance in a clinical isolate of *Staphylococcus aureus*. Lancet 2001; 358: 207-8.

32.   Wilson P, Andrews JA, Charlesworth R, Walesby R, Singer M, Farrell DJ et al. Linezolid resistance in clinical isolates of *Staphylococcus aureus*. J Antimicrob Chemother 2003; 51: 186-8.

33.   Tunger A, Aydemir S, Uluer S, Cilli F. In vitro activity of linezolid and quinupristin/dalfopristin against gram-positive cocci. Indian J Med Res 2004; 120(6): 546-52.

34.   Baysallar M, Kilic A, Aydogan H, Cilli F, Doganci L. Linezolid and quinopristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant *Staphylococcus aureus* prior to clinical use in Turkey. Int J Antimicrob Agents 2004; 23: 510-2.

35.   Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant *Staphylococcus aureus*. Am J Surg 2005; 189: 425-8.

36.   Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004; 188: 760-6.

37.   Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant *Staphylococcus aureus* in Japan. J Antimicrob Chemother 2007; 60: 1361-9.

38.   Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).Diagn Microbiol Infect Dis 2005; 52: 215-27.

39.   Grolman DC. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections. Int J Infect Dis 2007; 11 Suppl 1: S7-15

40.   Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G et al. 307 Study Group. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant *Staphylococcus aureus* or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62 Suppl 1: i17-28.